IL18 and diabetes mellitus: More importantly, after 12-week treatment with dapagliflozin in DM mice, the serum levels of NLRP3 (p < 0.01), IL-1β (p < 0.05), and IL-18 (p < 0.05) proteins were all significantly reduced, while NLRP3 and IL-18 levels were not significantly affected (Figure 2).